1-3 of 3
Eunju Hurh
Close
Sort by
Journal Articles

CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, Is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic When Combined with Pomalidomide

Laura L Poling, David Cocozziello, Minsheng He, Eunju Hurh, Riadh Lobbardi, Katrina L Jackson, Stewart L Fisher, Roy M Pollock
Journal: Blood
Blood (2023) 142 (Supplement 1): 6594.
https://doi.org/10.1182/blood-2023-174555
Published: 2023
Journal Articles

Phase 1b Dose-Escalation Study of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis

Vikas Gupta, MD FRCP, FRCPath, Steffen Koschmieder, MD, Claire N. Harrison, DM, FRCP, FRCPath, Francisco Cervantes, MD PhD, Florian H Heidel, MD, Mark Drummond, MD PhD, Jerome Rey, MD, Eunju Hurh, PhD, Weichao Bao, PhD, Anita Rampersad, Stacey Kalambakas, MD, Alessandro Maria Vannucchi, MD
Journal: Blood
Blood (2014) 124 (21): 712.
https://doi.org/10.1182/blood.V124.21.712.712
Published: 2014
Journal Articles

Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

Clinical Trials & Observations
Mitch A. Phelps, Thomas S. Lin, Amy J. Johnson, Eunju Hurh, Darlene M. Rozewski, Katherine L. Farley, Di Wu, Kristie A. Blum, Beth Fischer, Sarah M. Mitchell, Mollie E. Moran, Michelle Brooker-McEldowney, Nyla A. Heerema, David Jarjoura, Larry J. Schaaf, John C. Byrd, Michael R. Grever, James T. Dalton
Journal: Blood
Blood (2009) 113 (12): 2637–2645.
https://doi.org/10.1182/blood-2008-07-168583
Published: 2009